CN101969990B - 增强针对艾美球虫属的免疫反应的组合物和方法 - Google Patents

增强针对艾美球虫属的免疫反应的组合物和方法 Download PDF

Info

Publication number
CN101969990B
CN101969990B CN200880116875.0A CN200880116875A CN101969990B CN 101969990 B CN101969990 B CN 101969990B CN 200880116875 A CN200880116875 A CN 200880116875A CN 101969990 B CN101969990 B CN 101969990B
Authority
CN
China
Prior art keywords
vaccine
seq
polypeptide
trap
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880116875.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN101969990A (zh
Inventor
W·博特吉
B·哈格斯
L·博格曼
Y·M·权
K·乔菜
M·考克斯
S·莱顿
S·艾-阿什拉姆
J·巴尔塔
G·特列斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Guelph
Texas A&M University
University of Arkansas at Little Rock
Original Assignee
University of Guelph
Texas A&M University
University of Arkansas at Little Rock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Guelph, Texas A&M University, University of Arkansas at Little Rock filed Critical University of Guelph
Priority to CN201410081760.XA priority Critical patent/CN103893747B/zh
Publication of CN101969990A publication Critical patent/CN101969990A/zh
Application granted granted Critical
Publication of CN101969990B publication Critical patent/CN101969990B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/455—Eimeria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN200880116875.0A 2007-11-01 2008-11-03 增强针对艾美球虫属的免疫反应的组合物和方法 Active CN101969990B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410081760.XA CN103893747B (zh) 2007-11-01 2008-11-03 增强针对艾美球虫属的免疫反应的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98461207P 2007-11-01 2007-11-01
US60/984,612 2007-11-01
PCT/US2008/082254 WO2009059298A2 (en) 2007-11-01 2008-11-03 Compositions and methods of enhancinc immune responses to eimeria

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410081760.XA Division CN103893747B (zh) 2007-11-01 2008-11-03 增强针对艾美球虫属的免疫反应的组合物和方法

Publications (2)

Publication Number Publication Date
CN101969990A CN101969990A (zh) 2011-02-09
CN101969990B true CN101969990B (zh) 2014-07-09

Family

ID=40591796

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880116875.0A Active CN101969990B (zh) 2007-11-01 2008-11-03 增强针对艾美球虫属的免疫反应的组合物和方法
CN201410081760.XA Expired - Fee Related CN103893747B (zh) 2007-11-01 2008-11-03 增强针对艾美球虫属的免疫反应的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410081760.XA Expired - Fee Related CN103893747B (zh) 2007-11-01 2008-11-03 增强针对艾美球虫属的免疫反应的组合物和方法

Country Status (14)

Country Link
US (3) US8956849B2 (enExample)
EP (2) EP2214701B1 (enExample)
JP (1) JP5480812B2 (enExample)
CN (2) CN101969990B (enExample)
AU (1) AU2008318357B2 (enExample)
BR (1) BRPI0819229B1 (enExample)
CA (3) CA2704422C (enExample)
DK (2) DK3097926T3 (enExample)
ES (2) ES2599905T3 (enExample)
HU (2) HUE047164T2 (enExample)
NZ (2) NZ601880A (enExample)
PL (2) PL3097926T3 (enExample)
PT (2) PT2214701T (enExample)
WO (1) WO2009059298A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2520026T3 (es) * 2006-09-18 2014-11-11 The Board Of Trustees Of The University Of Arkansas Composiciones y métodos para potenciar respuestas inmunitarias
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
BRPI0818736A2 (pt) 2007-10-30 2017-06-13 Univ Arkansas composições e métodos para intensificar imunorrepostas à bactéria flagelada
CN101969990B (zh) * 2007-11-01 2014-07-09 阿肯色大学评议会 增强针对艾美球虫属的免疫反应的组合物和方法
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
CN102971008B (zh) 2010-06-09 2015-11-25 阿肯色大学评议会 降低弯曲菌属感染的疫苗和方法
AU2013203641B2 (en) * 2011-04-13 2014-08-21 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
US9580482B2 (en) 2012-02-17 2017-02-28 Children's Medical Center Corporation Conformation-stabilized TRAP antigens
US9603915B2 (en) 2013-02-14 2017-03-28 The Board of Trustees of the University of Akansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
BR112015023024B1 (pt) 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
CN107787365B (zh) 2015-05-08 2022-03-08 诺维信公司 α-淀粉酶变体以及编码其的多核苷酸
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN110468069B (zh) * 2019-08-19 2020-11-06 中国水产科学研究院长江水产研究所 一种干酪乳杆菌yfi-5及其在抗鲤疱疹病毒ii型中的应用
CN113304254A (zh) * 2021-06-07 2021-08-27 吉林大学 一种微小隐孢子虫Cp15重组侵入型乳酸菌活载体疫苗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1592751A (zh) * 2001-07-06 2005-03-09 Abic特瓦生物实验室有限公司 编码重组的来源于巨型艾美球虫子孢子/裂殖子的250kDa抗原的核酸,和它们的应用
CN1606565A (zh) * 2001-07-06 2005-04-13 Abic特瓦生物实验室有限公司 编码重组的来源于巨型艾美球虫配子母细胞的56和82kDa抗原的核酸和它们的应用

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL170938B1 (pl) 1991-03-05 1997-02-28 Wellcome Found Sposób wytwarzania szczepionki przeciwko infekcjom Salmonella PL PL
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
CA2121798C (en) 1991-10-25 2007-07-24 Richard J. Armitage Novel cytokine
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
CA2143299A1 (en) 1992-09-04 1994-03-17 Brenda J. Allan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
JP4242447B2 (ja) * 1993-01-22 2009-03-25 イミュネックス・コーポレーション Ｃｄ４０リガンド遺伝子の突然変異の検出および治療
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
CA2188165C (en) * 1994-04-28 2007-08-28 Marilyn Kehry Methods for proliferating and differentiating b cells, and uses thereof
NZ305083A (en) 1995-03-01 1999-06-29 Immunex Corp Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
CA2222914C (en) 1995-06-07 2002-04-02 Immunex Corporation Novel cd40l mutein
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
CA2313805A1 (en) 1997-12-19 1999-07-01 Immunex Corporation Method for reducing susceptibility to hiv infection
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
CA2341349C (en) 1998-09-04 2013-12-10 Creatogen Aktiengesellschaft Attenuated cells comprising sp12 mutants, carriers and compositions containing same, methods of production and uses thereof
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
JP2003508016A (ja) 1999-04-16 2003-03-04 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
US7803765B2 (en) * 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
US7118751B1 (en) * 1999-10-14 2006-10-10 Trubion Pharmaceuticals, Inc. DNA vaccines encoding antigen linked to a domain that binds CD40
PT1112747E (pt) 1999-12-28 2004-10-29 Akzo Nobel Nv Vacina de salmonella que nao induz anticorpos contra flagelina ou flagelos
CA2399790C (en) 2000-02-02 2012-10-30 Ralph A. Tripp Cd40 ligand adjuvant for respiratory syncytial virus
NZ521425A (en) 2000-03-17 2004-05-28 Upjohn Co Vaccine comprising a first attenuated non-reverting mutant Salmonella in which two or more secretion system apparatus genes have been inactivated
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
WO2002000232A2 (en) 2000-06-26 2002-01-03 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
WO2002036769A2 (en) 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
ES2329453T3 (es) 2001-05-15 2009-11-26 Ortho Mcneil Janssen Pharm Cebado ex-vivo para generar linfocitos t citotoxicos especificos del ligando cd40 para tratar enfermedades autoinmunitarias y alergicas.
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
WO2003028441A1 (en) 2001-10-02 2003-04-10 The Board Of Trustees Of The Leland Stanford Junior University Gene therapy for the prevention of autoimmune disease
MXPA04005909A (es) * 2001-12-21 2005-05-17 Immunex Corp Polipeptidos recombinantes.
AU2003215254A1 (en) * 2002-02-13 2003-09-04 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
WO2003096812A1 (en) 2002-04-15 2003-11-27 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005035570A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Variants of cd40l protein
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
CA2548347A1 (en) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
KR101243577B1 (ko) 2004-10-07 2013-03-20 아고스 쎄라퓨틱스, 인코포레이티드 성숙 수지상 세포 조성물 및 그의 배양 방법
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
WO2006130525A2 (en) 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
DE602006014720D1 (de) 2005-10-07 2010-07-15 Proyecto Biomedicina Cima Sl Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
JP2009514536A (ja) 2005-11-07 2009-04-09 シドニー キンメル キャンサー センター Ｃｄ４０リガンド融合蛋白質ワクチン
DE102005054643B3 (de) 2005-11-10 2007-02-15 Assa Abloy Sicherheitstechnik Gmbh Schließzylinder
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
CU23576A1 (es) * 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US8802419B2 (en) 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
FR2898905B1 (fr) * 2006-03-24 2008-05-09 Rhodia Recherches & Tech Composition polyisocyanate a proprietes anti-chocs ameliorees
US20090246220A1 (en) * 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
ES2520026T3 (es) 2006-09-18 2014-11-11 The Board Of Trustees Of The University Of Arkansas Composiciones y métodos para potenciar respuestas inmunitarias
US20100292309A1 (en) 2007-03-08 2010-11-18 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
CN101024076B (zh) * 2007-03-29 2010-08-18 中国农业大学 球虫的新用途
CA2963124C (en) * 2007-07-10 2019-10-15 Apogenix Ag Tnf superfamily collectin fusion proteins
BRPI0818736A2 (pt) 2007-10-30 2017-06-13 Univ Arkansas composições e métodos para intensificar imunorrepostas à bactéria flagelada
CN101969990B (zh) * 2007-11-01 2014-07-09 阿肯色大学评议会 增强针对艾美球虫属的免疫反应的组合物和方法
PL2310509T3 (pl) * 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
US8316310B2 (en) 2008-08-05 2012-11-20 International Business Machines Corporation System and method for human identification proof for use in virtual environments
EP2184229B1 (en) * 2008-11-11 2012-10-17 AGUSTAWESTLAND S.p.A. Helicopter rotor
US20100150958A1 (en) * 2008-12-15 2010-06-17 Vectogen Pty Ltd. Methods and Compositions for Use of a Coccidiosis Vaccine
CN102811734B (zh) * 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
SG10201707813YA (en) * 2011-10-11 2017-11-29 Medimmune Llc Cd40l-specific tn3-derived scaffolds and methods of use thereof
WO2014043215A1 (en) * 2012-09-11 2014-03-20 The Texas A&M University System Bi-specifc diabodies for masking and targeting vaccines
DK2911676T3 (da) * 2012-10-29 2020-08-03 Univ Arkansas Hidtil ukendte mukosale adjuvanser og afgivelsessystemer
US9603915B2 (en) * 2013-02-14 2017-03-28 The Board of Trustees of the University of Akansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
BR112015023024B1 (pt) * 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
US20170196971A1 (en) * 2014-06-05 2017-07-13 The Board Of Trustees Of The University Of Arkansas Antibody guided vaccines and methods of use for generation of rapid mature immune responses
US20160090603A1 (en) * 2014-09-30 2016-03-31 Sandia Corporation Delivery platforms for the domestication of algae and plants
AU2017244108B2 (en) * 2016-03-29 2021-03-18 University Of Southern California Chimeric antigen receptors targeting cancer
SG10201914132RA (en) * 2016-05-27 2020-03-30 Abbvie Biotherapeutics Inc Anti-cd40 antibodies and their uses
CN109803977B (zh) * 2016-08-17 2023-03-17 菲克特生物科学股份有限公司 核酸产品及其施用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1592751A (zh) * 2001-07-06 2005-03-09 Abic特瓦生物实验室有限公司 编码重组的来源于巨型艾美球虫子孢子/裂殖子的250kDa抗原的核酸,和它们的应用
CN1606565A (zh) * 2001-07-06 2005-04-13 Abic特瓦生物实验室有限公司 编码重组的来源于巨型艾美球虫配子母细胞的56和82kDa抗原的核酸和它们的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Maternal Immunization with Gametocyte Antigens as a Means of Providing Protective Immunity against Eimeria maxima in Chickens;MICHAEL WALLACH, et al.;《INFECTION AND IMMUNITY》;19920531;第60卷(第5期);2036-2039 *

Also Published As

Publication number Publication date
JP5480812B2 (ja) 2014-04-23
CA3051748A1 (en) 2009-05-07
DK2214701T3 (en) 2016-12-12
AU2008318357A2 (en) 2010-06-24
NZ601880A (en) 2013-12-20
EP2214701B1 (en) 2016-08-03
CA2704422C (en) 2019-09-24
WO2009059298A3 (en) 2009-09-24
PL3097926T3 (pl) 2020-04-30
CA2704422A1 (en) 2009-05-07
DK3097926T3 (da) 2019-12-16
JP2011503003A (ja) 2011-01-27
US8956849B2 (en) 2015-02-17
HUE030655T2 (en) 2017-05-29
WO2009059298A8 (en) 2010-08-05
EP2214701A2 (en) 2010-08-11
CA3051748C (en) 2022-07-12
PT3097926T (pt) 2020-01-08
CA3156538A1 (en) 2009-05-07
HUE047164T2 (hu) 2020-04-28
CN103893747A (zh) 2014-07-02
NZ585777A (en) 2012-09-28
HK1146575A1 (zh) 2011-06-24
EP3097926B1 (en) 2019-10-02
AU2008318357A1 (en) 2009-05-07
US20150216954A1 (en) 2015-08-06
CN103893747B (zh) 2016-01-06
US10842858B2 (en) 2020-11-24
US20180333474A1 (en) 2018-11-22
PL2214701T3 (pl) 2017-01-31
US20110111015A1 (en) 2011-05-12
US10016493B2 (en) 2018-07-10
CN101969990A (zh) 2011-02-09
EP2214701A4 (en) 2011-06-01
EP3097926A1 (en) 2016-11-30
AU2008318357B2 (en) 2015-01-22
WO2009059298A2 (en) 2009-05-07
BRPI0819229B1 (pt) 2019-01-22
PT2214701T (pt) 2016-11-02
BRPI0819229A2 (pt) 2015-05-05
ES2761693T3 (es) 2020-05-20
ES2599905T3 (es) 2017-02-06
CA3156538C (en) 2023-12-12

Similar Documents

Publication Publication Date Title
CN101969990B (zh) 增强针对艾美球虫属的免疫反应的组合物和方法
EP2214840B1 (en) Compositions and methods of enhancing immune responses to flagellated bacterium
AU2015202009B2 (en) Compositions and methods of enhancing immune responses to eimeria
HK1231742B (en) Compositions and methods of enhancing immune responses to eimeria
HK1231742A1 (en) Compositions and methods of enhancing immune responses to eimeria
HK1231742A (en) Compositions and methods of enhancing immune responses to eimeria
HK1146575B (en) Compositions and methods of enhancing immune responses to eimeria
HK1146644B (en) Compositions and methods of enhancing immune responses to flagellated bacterium

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: American Arkansas

Applicant after: Texas A. & M. Univ Sys

Applicant after: Texas A & M University System Guelph University

Address before: Arizona, USA

Applicant before: Texas A. & M. Univ Sys

Applicant before: Texas A & M University System Guelph University

C14 Grant of patent or utility model
GR01 Patent grant